SG10202100295RA - Novel peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers - Google Patents

Novel peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers

Info

Publication number: SG10202100295RA
Authority: SG; Singapore
Prior art keywords: peptides; cancers; combination; ovarian cancer; epithelial ovarian
Prior art date: 2015-07-15

Application number

SG10202100295RA

Inventor

Heiko Schuster

Janet Peper

Philipp Wagner

Hans-Georg Rammensee

Original Assignee

Immatics Biotechnologies Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-07-15

Filing date

2016-07-14

Publication date

2021-02-25

2016-07-14 Application filed by Immatics Biotechnologies Gmbh filed Critical Immatics Biotechnologies Gmbh

2021-02-25 Publication of SG10202100295RA publication Critical patent/SG10202100295RA/en

Links

102000004196 processed proteins & peptides Human genes 0.000 title 2
108090000765 processed proteins & peptides Proteins 0.000 title 2
206010028980 Neoplasm Diseases 0.000 title 1
208000007571 Ovarian Epithelial Carcinoma Diseases 0.000 title 1
206010033128 Ovarian cancer Diseases 0.000 title 1
238000009169 immunotherapy Methods 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464466—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
- A61K39/464468—Mesothelin [MSLN]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464469—Tumor associated carbohydrates
- A61K39/46447—Mucins, e.g. MUC-1
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4727—Mucins, e.g. human intestinal mucin
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/16—Aptamers
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/70539—MHC-molecules, e.g. HLA-molecules
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

SG10202100295RA 2015-07-15 2016-07-14 Novel peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers SG10202100295RA (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201562192670P	2015-07-15	2015-07-15
GBGB1512369.8A GB201512369D0 (en)	2015-07-15	2015-07-15	Novel peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers

Publications (1)

Publication Number	Publication Date
SG10202100295RA true SG10202100295RA (en)	2021-02-25

Family

ID=54013984

Family Applications (7)

Application Number	Title	Priority Date	Filing Date
SG10202100294WA SG10202100294WA (en)	2015-07-15	2016-07-14	Novel peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers
SG10202100292VA SG10202100292VA (en)	2015-07-15	2016-07-14	Novel peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers
SG10202100298SA SG10202100298SA (en)	2015-07-15	2016-07-14	Novel peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers
SG10202100291XA SG10202100291XA (en)	2015-07-15	2016-07-14	Novel peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers
SG10202100297QA SG10202100297QA (en)	2015-07-15	2016-07-14	Novel peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers
SG10202100296PA SG10202100296PA (en)	2015-07-15	2016-07-14	Novel peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers
SG10202100295RA SG10202100295RA (en)	2015-07-15	2016-07-14	Novel peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers

Family Applications Before (6)

Application Number	Title	Priority Date	Filing Date
SG10202100294WA SG10202100294WA (en)	2015-07-15	2016-07-14	Novel peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers
SG10202100292VA SG10202100292VA (en)	2015-07-15	2016-07-14	Novel peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers
SG10202100298SA SG10202100298SA (en)	2015-07-15	2016-07-14	Novel peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers
SG10202100291XA SG10202100291XA (en)	2015-07-15	2016-07-14	Novel peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers
SG10202100297QA SG10202100297QA (en)	2015-07-15	2016-07-14	Novel peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers
SG10202100296PA SG10202100296PA (en)	2015-07-15	2016-07-14	Novel peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers

Country Status (37)

Country	Link
US (22)	US9889159B2 (en)
EP (2)	EP3322717B1 (en)
JP (10)	JP6862411B2 (en)
KR (2)	KR20180030506A (en)
CN (2)	CN107922469A (en)
AU (4)	AU2016293047B9 (en)
BR (2)	BR112017028558A2 (en)
CA (2)	CA3221097A1 (en)
CL (5)	CL2018000124A1 (en)
CO (1)	CO2018000252A2 (en)
CR (4)	CR20200410A (en)
CY (1)	CY1123505T1 (en)
DK (1)	DK3322717T3 (en)
EA (1)	EA201890027A1 (en)
ES (1)	ES2807832T3 (en)
GB (1)	GB201512369D0 (en)
HK (1)	HK1253574A1 (en)
HR (1)	HRP20201281T1 (en)
HU (1)	HUE049937T2 (en)
IL (3)	IL292131A (en)
LT (1)	LT3322717T (en)
MA (3)	MA41717A1 (en)
MD (1)	MD3322717T2 (en)
ME (1)	ME03808B (en)
MX (1)	MX2018000543A (en)
MY (1)	MY189596A (en)
NZ (1)	NZ739128A (en)
PE (1)	PE20180693A1 (en)
PH (1)	PH12018500005A1 (en)
PL (1)	PL3322717T3 (en)
PT (1)	PT3322717T (en)
RS (1)	RS60647B1 (en)
SG (7)	SG10202100294WA (en)
SI (1)	SI3322717T1 (en)
UA (1)	UA124875C2 (en)
WO (1)	WO2017009400A1 (en)
ZA (1)	ZA201800129B (en)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ME03300B (en)	2012-06-13	2019-07-20	Incyte Holdings Corp	Substituted tricyclic compounds as fgfr inhibitors
DK2986610T5 (en)	2013-04-19	2018-12-10	Incyte Holdings Corp	BICYCLIC HETEROCYCLES AS FGFR INHIBITORS
US10851105B2 (en)	2014-10-22	2020-12-01	Incyte Corporation	Bicyclic heterocycles as FGFR4 inhibitors
MA41551A (en)	2015-02-20	2017-12-26	Incyte Corp	BICYCLIC HETEROCYCLES USED AS FGFR4 INHIBITORS
EA038045B1 (en)	2015-02-20	2021-06-28	Инсайт Корпорейшн	Bicyclic heterocycles as fgfr inhibitors
GB201507030D0 (en) *	2015-04-24	2015-06-10	Immatics Biotechnologies Gmbh	Immunotherapy against lung cancers, in particular NSCLC
GB201512369D0 (en) *	2015-07-15	2015-08-19	Immatics Biotechnologies Gmbh	Novel peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers
IL259931B2 (en)	2015-12-16	2024-02-01	Gritstone Bio Inc	Neoantigen identification, manufacture, and use
GB201609193D0 (en)	2016-05-25	2016-07-06	Immatics Biotechnologies Gmbh	Novel peptides, combination of peptides as targets for use in immunotherapy against gallbladder cancer and cholangiocarcinoma and other cancers
JP7075125B2 (en)	2016-05-25	2022-05-25	イマティクスバイオテクノロジーズゲーエムベーハー	A novel peptide, peptide combination as a target and for use in immunotherapy for gallbladder cancer and cholangiocarcinoma and other cancers
DE102016123893A1 (en)	2016-12-08	2018-06-14	Immatics Biotechnologies Gmbh	T cell receptors with improved binding
EP4317432A3 (en)	2016-12-08	2024-04-17	Immatics Biotechnologies GmbH	T cell receptors with improved pairing
AR110857A1 (en)	2017-01-27	2019-05-08	Immatics Biotechnologies Gmbh	PEPTIDES AND COMBINATIONS OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST OVARIAN CANCER AND OTHER TYPES OF CANCER
MA47367B1 (en) *	2017-01-27	2023-06-28	Immatics Biotechnologies Gmbh	NOVEL PEPTIDES AND COMBINATIONS OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST OVARIAN CANCER AND OTHER CANCERS
EP3573647B1 (en) *	2017-01-27	2023-04-05	Immatics Biotechnologies GmbH	Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
AR111960A1 (en)	2017-05-26	2019-09-04	Incyte Corp	CRYSTALLINE FORMS OF A FGFR INHIBITOR AND PROCESSES FOR ITS PREPARATION
HRP20211744T1 (en)	2017-07-14	2022-02-04	Immatics Biotechnologies Gmbh	Improved dual specificity polypeptide molecule
AU2018348165A1 (en)	2017-10-10	2020-05-21	Gritstone Bio, Inc.	Neoantigen identification using hotspots
KR20200090855A (en)	2017-11-22	2020-07-29	그릿스톤 온콜로지, 인코포레이티드	Reduced presentation of conjugated epitopes for new antigens
DE102017127984B4 (en)	2017-11-27	2019-12-05	Immatics US, Inc.	Method for the propagation and activation of γδ T cells
MA51792A (en)	2018-02-09	2020-12-16	Immatics Us Inc	T LYMPHOCYTES MANUFACTURING PROCESSES
EA202092649A1 (en)	2018-05-04	2021-06-21	Инсайт Корпорейшн	FGFR INHIBITOR SALTS
US11466004B2 (en)	2018-05-04	2022-10-11	Incyte Corporation	Solid forms of an FGFR inhibitor and processes for preparing the same
CN110531077B (en) *	2018-05-25	2023-07-07	荣昌生物制药(烟台)股份有限公司	Mesothelin immunohistochemical detection kit
WO2020028562A1 (en) *	2018-07-31	2020-02-06	Loma Linda University	Snail sirna-loaded mesoporous silica nanoparticles
US11628162B2 (en)	2019-03-08	2023-04-18	Incyte Corporation	Methods of treating cancer with an FGFR inhibitor
US20200297768A1 (en)	2019-03-19	2020-09-24	Immatics US, Inc.	Cd28 t cell cultures, compositions, and methods of using thereof
PE20220164A1 (en)	2019-05-27	2022-01-28	Immatics Us Inc	VIRAL VECTORS AND THEIR USE IN ADOPTIVE CELLULAR THERAPIES
BR112021024540A2 (en)	2019-06-06	2022-03-22	Immatics Biotechnologies Gmbh	Methods for selecting a cell or a virus, determining the sequence of a nucleic acid, producing a cell that expresses a nucleic acid and treating a subject, selected immune cell and method for selecting an immune cell
US20220354937A1 (en) *	2019-06-25	2022-11-10	Universite De Montreal	Novel tumor-specific antigens for ovarian cancer and uses thereof
US11591329B2 (en)	2019-07-09	2023-02-28	Incyte Corporation	Bicyclic heterocycles as FGFR inhibitors
US20210032370A1 (en)	2019-08-02	2021-02-04	Immatics Biotechnologies Gmbh	Recruiting agent further binding an mhc molecule
IL291901A (en)	2019-10-14	2022-06-01	Incyte Corp	Bicyclic heterocycles as fgfr inhibitors
WO2021076728A1 (en)	2019-10-16	2021-04-22	Incyte Corporation	Bicyclic heterocycles as fgfr inhibitors
WO2021113479A1 (en)	2019-12-04	2021-06-10	Incyte Corporation	Tricyclic heterocycles as fgfr inhibitors
KR20220131900A (en)	2019-12-04	2022-09-29	인사이트 코포레이션	Derivatives of FGFR inhibitors
MX2022010461A (en)	2020-02-24	2022-12-13	Immatics Us Inc	Methods for expanding t cells for the treatment of cancer and related malignancies.
DE102020106710A1 (en)	2020-03-11	2021-09-16	Immatics US, Inc.	WPRE MUTANT CONSTRUCTS, COMPOSITIONS, AND RELATED PROCEDURES
DE102020111571A1 (en)	2020-03-11	2021-09-16	Immatics US, Inc.	WPRE MUTANT CONSTRUCTS, COMPOSITIONS, AND RELATED PROCEDURES
WO2022040631A1 (en)	2020-08-21	2022-02-24	Immatics US, Inc.	Methods for isolating cd8+ selected t cells
JP2024502034A (en)	2020-12-31	2024-01-17	イマティクスユーエス，アイエヌシー．	CD8 polypeptides, compositions, and methods of using them
CN117222734A (en) *	2021-04-23	2023-12-12	Vlp 治疗有限责任公司	Galectin-targeted immunotherapy
US20220356252A1 (en)	2021-05-05	2022-11-10	Immatics Biotechnologies Gmbh	Bma031 antigen binding polypeptides
AR126102A1 (en)	2021-06-09	2023-09-13	Incyte Corp	TRICYCLIC HETEROCYCLES AS FGFR INHIBITORS
WO2023025851A1 (en) *	2021-08-24	2023-03-02	Immatics US, Inc.	Selection of immune cells using peptide mhc complexes generated by conditional ligand exchange
US20230089392A1 (en)	2021-09-20	2023-03-23	Immatics US, Inc.	Monocyte depletion of t cells populations for t-cell therapy
US20230192886A1 (en)	2021-11-08	2023-06-22	Immatics Biotechnologies Gmbh	Adoptive cell therapy combination treatment and compositions thereof
WO2023212655A1 (en)	2022-04-28	2023-11-02	Immatics US, Inc.	Il-12 polypeptides, il-15 polypeptides, il-18 polypeptides, cd8 polypeptides, compositions, and methods of using thereof
WO2023212691A1 (en)	2022-04-28	2023-11-02	Immatics US, Inc.	DOMINANT NEGATIVE TGFβ RECEPTOR POLYPEPTIDES, CD8 POLYPEPTIDES, CELLS, COMPOSITIONS, AND METHODS OF USING THEREOF
WO2023212697A1 (en)	2022-04-28	2023-11-02	Immatics US, Inc.	Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof
US20230355678A1 (en)	2022-05-05	2023-11-09	Immatics US, Inc.	Methods for improving t cell efficacy
CN114657158B (en) *	2022-05-25	2022-10-21	深圳吉诺因生物科技有限公司	IDO 1-related vaccine and application thereof

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1575500A4 (en) *	2002-07-12	2007-01-03	Univ Johns Hopkins	Mesothelin vaccines and model systems
AU2003299643A1 (en) *	2002-12-04	2004-06-23	Diadexus, Inc.	Compositions, splice variants and methods relating to colon specific genes and proteins
DE102004026135A1 (en)	2004-05-25	2006-01-05	Immatics Biotechnologies Gmbh	Tumor-associated peptides binding to MHC molecules
EP1804830A2 (en) *	2004-09-08	2007-07-11	The Ludwig Institute for Cancer Research	Cancer-testis antigens
WO2006106912A1 (en) *	2005-03-31	2006-10-12	Chugai Seiyaku Kabushiki Kaisha	Cancer-associated antigen analog peptide and utilization of the same
PL1760089T3 (en) *	2005-09-05	2010-03-31	Immatics Biotechnologies Gmbh	Tumor-associated peptides binding to human leukocyte antigen (HLA) class I or II molecules and related anti-cancer vaccine
PT1806359E (en)	2005-09-05	2010-05-25	Immatics Biotechnologies Gmbh	Tumor-associated peptides binding promiscuously to human leukocyte antigen (hla) class ii molecules
ES2603418T3 (en) *	2006-10-04	2017-02-27	Janssen Pharmaceutica Nv	Preparation of inactivated artificial antigen presenting cells and their use in cell therapies
WO2008127285A2 (en) *	2006-10-05	2008-10-23	The Board Of Trustees Of The University Of Arkansas	Target peptides for ovarian cancer immunotherapy
NZ582822A (en) *	2007-07-27	2012-06-29	Immatics Biotechnologies Gmbh	Novel immunogenic epitopes for immunotherapy
PT2183361E (en) *	2007-07-27	2015-09-11	Immatics Biotechnologies Gmbh	Novel immunotherapy against brain tumors
US20100260764A1 (en) *	2007-08-29	2010-10-14	Marinkovich M Peter	Compositions and methods for inhibiting squamous cell carcinoma
HUE024541T2 (en) *	2008-05-14	2016-01-28	Immatics Biotechnologies Gmbh	Novel and powerful MHC-class II peptides derived from survivin and neurocan
ES2536465T3 (en) *	2008-10-01	2015-05-25	Immatics Biotechnologies Gmbh	Composition of tumor-associated and cancer-related peptides for the treatment of glioblastoma (GBM) and other cancers
GB201004551D0 (en)	2010-03-19	2010-05-05	Immatics Biotechnologies Gmbh	NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
GB201006360D0 (en) *	2010-04-16	2010-06-02	Immatics Biotechnologies Gmbh	Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development
US9688991B2 (en) *	2012-07-13	2017-06-27	Albert Einstein College Of Medicine, Inc.	Aptamer-targetted antigen delivery
MY171854A (en) *	2013-03-29	2019-11-05	Sumitomo Dainippon Pharma Co Ltd	Wt1 antigen peptide conjugate vaccine
TWI775117B (en)	2013-08-05	2022-08-21	德商伊瑪提克斯生物科技有限公司	Novel peptides, cells, and their use against several tumors, methods for production thereof and pharmaceutical composition comprising the same
GB201319446D0 (en) *	2013-11-04	2013-12-18	Immatics Biotechnologies Gmbh	Personalized immunotherapy against several neuronal and brain tumors
GB201505305D0 (en) *	2015-03-27	2015-05-13	Immatics Biotechnologies Gmbh	Novel Peptides and combination of peptides for use in immunotherapy against various tumors
KR20220167337A (en) *	2015-03-27	2022-12-20	이매틱스 바이오테크놀로지스 게엠베하	Novel peptides and combination of peptides for use in immunotherapy against various tumors
GB201507030D0 (en)	2015-04-24	2015-06-10	Immatics Biotechnologies Gmbh	Immunotherapy against lung cancers, in particular NSCLC
GB201512369D0 (en)	2015-07-15	2015-08-19	Immatics Biotechnologies Gmbh	Novel peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers

2015
- 2015-07-15 GB GBGB1512369.8A patent/GB201512369D0/en not_active Ceased
- 2015-07-15 MY MYPI2018700111A patent/MY189596A/en unknown
2016
- 2016-07-14 IL IL292131A patent/IL292131A/en unknown
- 2016-07-14 LT LTEP16739102.8T patent/LT3322717T/en unknown
- 2016-07-14 ME MEP-2020-159A patent/ME03808B/en unknown
- 2016-07-14 ES ES16739102T patent/ES2807832T3/en active Active
- 2016-07-14 UA UAA201712985A patent/UA124875C2/en unknown
- 2016-07-14 MD MDE20180524T patent/MD3322717T2/en unknown
- 2016-07-14 WO PCT/EP2016/066706 patent/WO2017009400A1/en active Application Filing
- 2016-07-14 JP JP2018501316A patent/JP6862411B2/en active Active
- 2016-07-14 CR CR20200410A patent/CR20200410A/en unknown
- 2016-07-14 CN CN201680041146.8A patent/CN107922469A/en active Pending
- 2016-07-14 CR CR20200409A patent/CR20200409A/en unknown
- 2016-07-14 KR KR1020187000652A patent/KR20180030506A/en not_active IP Right Cessation
- 2016-07-14 EP EP16739102.8A patent/EP3322717B1/en active Active
- 2016-07-14 CA CA3221097A patent/CA3221097A1/en active Pending
- 2016-07-14 SI SI201630868T patent/SI3322717T1/en unknown
- 2016-07-14 BR BR112017028558-4A patent/BR112017028558A2/en active Search and Examination
- 2016-07-14 SG SG10202100294WA patent/SG10202100294WA/en unknown
- 2016-07-14 CN CN202111534523.0A patent/CN114163501A/en active Pending
- 2016-07-14 CA CA2992506A patent/CA2992506A1/en active Pending
- 2016-07-14 MA MA41717A patent/MA41717A1/en unknown
- 2016-07-14 RS RS20200937A patent/RS60647B1/en unknown
- 2016-07-14 HU HUE16739102A patent/HUE049937T2/en unknown
- 2016-07-14 NZ NZ739128A patent/NZ739128A/en unknown
- 2016-07-14 US US15/209,845 patent/US9889159B2/en active Active
- 2016-07-14 CR CR20180027A patent/CR20180027A/en unknown
- 2016-07-14 PE PE2018000052A patent/PE20180693A1/en unknown
- 2016-07-14 SG SG10202100292VA patent/SG10202100292VA/en unknown
- 2016-07-14 SG SG10202100298SA patent/SG10202100298SA/en unknown
- 2016-07-14 MA MA050542A patent/MA50542A/en unknown
- 2016-07-14 IL IL308200A patent/IL308200A/en unknown
- 2016-07-14 DK DK16739102.8T patent/DK3322717T3/en active
- 2016-07-14 SG SG10202100291XA patent/SG10202100291XA/en unknown
- 2016-07-14 KR KR1020227017673A patent/KR20220075451A/en not_active Application Discontinuation
- 2016-07-14 MA MA42441A patent/MA42441B1/en unknown
- 2016-07-14 SG SG10202100297QA patent/SG10202100297QA/en unknown
- 2016-07-14 AU AU2016293047A patent/AU2016293047B9/en active Active
- 2016-07-14 EP EP20170212.3A patent/EP3705491A1/en active Pending
- 2016-07-14 BR BR122023024959-3A patent/BR122023024959A2/en unknown
- 2016-07-14 EA EA201890027A patent/EA201890027A1/en unknown
- 2016-07-14 CR CR20200408A patent/CR20200408A/en unknown
- 2016-07-14 PT PT167391028T patent/PT3322717T/en unknown
- 2016-07-14 PL PL16739102T patent/PL3322717T3/en unknown
- 2016-07-14 SG SG10202100296PA patent/SG10202100296PA/en unknown
- 2016-07-14 MX MX2018000543A patent/MX2018000543A/en unknown
- 2016-07-14 SG SG10202100295RA patent/SG10202100295RA/en unknown
2017
- 2017-11-15 US US15/813,610 patent/US10463696B2/en active Active
2018
- 2018-01-02 IL IL256697A patent/IL256697B/en unknown
- 2018-01-03 PH PH12018500005A patent/PH12018500005A1/en unknown
- 2018-01-08 ZA ZA2018/00129A patent/ZA201800129B/en unknown
- 2018-01-12 CO CONC2018/0000252A patent/CO2018000252A2/en unknown
- 2018-01-15 CL CL2018000124A patent/CL2018000124A1/en unknown
- 2018-10-08 HK HK18112779.2A patent/HK1253574A1/en unknown
2019
- 2019-08-30 US US16/556,549 patent/US10639331B2/en active Active
- 2019-08-30 US US16/556,704 patent/US10639332B2/en active Active
- 2019-08-30 US US16/556,695 patent/US10568909B2/en active Active
- 2019-11-19 CL CL2019003310A patent/CL2019003310A1/en unknown
- 2019-11-19 CL CL2019003312A patent/CL2019003312A1/en unknown
- 2019-11-19 CL CL2019003311A patent/CL2019003311A1/en unknown
- 2019-11-19 CL CL2019003313A patent/CL2019003313A1/en unknown
2020
- 2020-01-31 US US16/777,919 patent/US10722538B2/en active Active
- 2020-03-24 JP JP2020052558A patent/JP7074367B2/en active Active
- 2020-03-30 JP JP2020059702A patent/JP7239992B2/en active Active
- 2020-04-06 JP JP2020068264A patent/JP7074369B2/en active Active
- 2020-04-13 JP JP2020071602A patent/JP7074370B2/en active Active
- 2020-04-20 JP JP2020074570A patent/JP7239993B2/en active Active
- 2020-04-27 JP JP2020078116A patent/JP2020182458A/en active Pending
- 2020-05-11 JP JP2020082964A patent/JP2020198875A/en active Pending
- 2020-05-18 JP JP2020086514A patent/JP7205919B2/en active Active
- 2020-05-25 JP JP2020090207A patent/JP2021000078A/en active Pending
- 2020-06-15 AU AU2020203971A patent/AU2020203971B2/en active Active
- 2020-06-18 US US16/905,499 patent/US10869897B2/en active Active
- 2020-06-18 US US16/905,530 patent/US10881690B2/en active Active
- 2020-06-18 US US16/905,550 patent/US10888587B2/en active Active
- 2020-08-13 HR HRP20201281TT patent/HRP20201281T1/en unknown
- 2020-09-08 CY CY20201100848T patent/CY1123505T1/en unknown
- 2020-10-13 AU AU2020256318A patent/AU2020256318A1/en not_active Abandoned
- 2020-12-09 US US17/116,635 patent/US11071756B2/en active Active
- 2020-12-16 US US17/123,585 patent/US20210106624A1/en not_active Abandoned
2021
- 2021-04-30 US US17/245,105 patent/US11246889B2/en active Active
- 2021-04-30 US US17/245,031 patent/US11806366B2/en active Active
- 2021-04-30 US US17/245,076 patent/US11278571B2/en active Active
- 2021-04-30 US US17/245,012 patent/US20210252064A1/en not_active Abandoned
- 2021-04-30 US US17/245,133 patent/US11819518B2/en active Active
2022
- 2022-02-04 AU AU2022200745A patent/AU2022200745B2/en active Active
- 2022-10-17 US US18/047,195 patent/US20230190813A1/en active Pending
- 2022-10-17 US US18/047,236 patent/US20230241107A1/en active Pending
- 2022-10-17 US US18/047,234 patent/US20230241106A1/en active Pending
- 2022-10-21 US US18/048,489 patent/US20230285458A1/en active Pending
- 2022-10-21 US US18/048,796 patent/US20230201259A1/en active Pending
- 2022-10-24 US US18/049,105 patent/US20230086100A1/en active Pending

Also Published As

Publication number	Publication date
LT3322717T (en)	2020-08-25
AU2020203971A1 (en)	2020-07-02
JP2020198875A (en)	2020-12-17
US11278571B2 (en)	2022-03-22
US10881690B2 (en)	2021-01-05
US20230190813A1 (en)	2023-06-22
KR20180030506A (en)	2018-03-23
AU2022200745B2 (en)	2024-01-18
CY1123505T1 (en)	2022-03-24
MA42441B1 (en)	2020-07-29
US20180117085A1 (en)	2018-05-03
JP2021000078A (en)	2021-01-07
US20200316127A1 (en)	2020-10-08
US20210260123A1 (en)	2021-08-26
US10888587B2 (en)	2021-01-12
US20210106623A1 (en)	2021-04-15
CR20200409A (en)	2020-10-16
CL2019003310A1 (en)	2020-04-24
EA201890027A1 (en)	2018-06-29
CO2018000252A2 (en)	2018-05-31
HRP20201281T1 (en)	2020-11-13
US9889159B2 (en)	2018-02-13
US20210260122A1 (en)	2021-08-26
US20210106624A1 (en)	2021-04-15
AU2016293047A2 (en)	2018-03-15
US11071756B2 (en)	2021-07-27
AU2016293047B2 (en)	2020-09-17
JP2020182458A (en)	2020-11-12
CN114163501A (en)	2022-03-11
JP6862411B2 (en)	2021-04-21
EP3705491A1 (en)	2020-09-09
CL2019003312A1 (en)	2020-03-13
US10639332B2 (en)	2020-05-05
JP7205919B2 (en)	2023-01-17
GB201512369D0 (en)	2015-08-19
MY189596A (en)	2022-02-18
HK1253574A1 (en)	2019-06-21
KR20220075451A (en)	2022-06-08
US10869897B2 (en)	2020-12-22
US20230241107A1 (en)	2023-08-03
SG10202100296PA (en)	2021-02-25
CL2019003313A1 (en)	2020-03-13
EP3322717B1 (en)	2020-06-10
US20200316125A1 (en)	2020-10-08
JP7074370B2 (en)	2022-05-24
SG10202100294WA (en)	2021-02-25
US10463696B2 (en)	2019-11-05
SG10202100292VA (en)	2021-02-25
AU2016293047B9 (en)	2020-10-29
EP3322717A1 (en)	2018-05-23
US20200155603A1 (en)	2020-05-21
WO2017009400A1 (en)	2017-01-19
ME03808B (en)	2021-04-20
NZ739128A (en)	2022-04-29
CR20200410A (en)	2020-10-12
AU2016293047A1 (en)	2018-02-08
AU2020256318A1 (en)	2020-11-12
PT3322717T (en)	2020-07-27
RS60647B1 (en)	2020-09-30
JP2020171283A (en)	2020-10-22
IL292131A (en)	2022-06-01
MX2018000543A (en)	2018-05-22
US20170035807A1 (en)	2017-02-09
CL2018000124A1 (en)	2018-05-18
US20210252065A1 (en)	2021-08-19
PL3322717T3 (en)	2020-11-16
JP2020167995A (en)	2020-10-15
CR20200408A (en)	2020-10-08
US20200000850A1 (en)	2020-01-02
US10568909B2 (en)	2020-02-25
CR20180027A (en)	2018-07-23
JP2020182451A (en)	2020-11-12
SG10202100298SA (en)	2021-02-25
CL2019003311A1 (en)	2020-03-13
JP7239992B2 (en)	2023-03-15
SG10202100297QA (en)	2021-02-25
BR112017028558A2 (en)	2018-09-04
US20230285458A1 (en)	2023-09-14
PE20180693A1 (en)	2018-04-23
JP2020127401A (en)	2020-08-27
US20230086100A1 (en)	2023-03-23
US20190381103A1 (en)	2019-12-19
CN107922469A (en)	2018-04-17
UA124875C2 (en)	2021-12-08
JP2020191862A (en)	2020-12-03
IL256697A (en)	2018-03-29
US11246889B2 (en)	2022-02-15
AU2020203971B2 (en)	2021-11-25
US20200316126A1 (en)	2020-10-08
MA41717A1 (en)	2019-05-31
US10639331B2 (en)	2020-05-05
SG10202100291XA (en)	2021-02-25
US20210252066A1 (en)	2021-08-19
MA50542A (en)	2020-09-09
HUE049937T2 (en)	2020-11-30
BR122023024959A2 (en)	2024-01-16
US11806366B2 (en)	2023-11-07
ES2807832T3 (en)	2021-02-24
AU2022200745A1 (en)	2022-02-24
CA2992506A1 (en)	2017-01-19
CA3221097A1 (en)	2017-01-19
IL308200A (en)	2024-01-01
JP2020156480A (en)	2020-10-01
IL256697B (en)	2022-05-01
US20230201259A1 (en)	2023-06-29
DK3322717T3 (en)	2020-08-10
MD3322717T2 (en)	2020-11-30
JP2018531581A (en)	2018-11-01
JP7074367B2 (en)	2022-05-24
US11819518B2 (en)	2023-11-21
US20230241106A1 (en)	2023-08-03
PH12018500005A1 (en)	2018-07-09
US20210252064A1 (en)	2021-08-19
US10722538B2 (en)	2020-07-28
US20200000849A1 (en)	2020-01-02
JP7239993B2 (en)	2023-03-15
JP7074369B2 (en)	2022-05-24
ZA201800129B (en)	2018-12-19
SI3322717T1 (en)	2020-09-30

Publication	Publication Date	Title
HK1253574A1 (en)	2019-06-21	Novel peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers
HK1252868A1 (en)	2019-06-06	Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
SG10202001665QA (en)	2020-04-29	Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
IL258599A (en)	2018-06-28	Novel peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers
GB201511792D0 (en)	2015-08-19	Novel peptides and combination of peptides for use in immunotherapy against esopageal cancer and other cancers
SG11201706155XA (en)	2017-09-28	Novel peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers
GB201522667D0 (en)	2016-02-03	Novel peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers
IL268278A (en)	2019-09-26	Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
HK1255542A1 (en)	2019-08-23	Novel peptides and combination of peptides for use in immunotherapy against esophageal cancer and other cancers
IL280879A (en)	2021-04-29	Novel peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers